- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07895628
A Crossover Study Evaluating the Postprandial Glycemic Response of Three Sweeteners in a Mixed Meal Setting
A Randomized, Participant-Masked, Crossover Study Evaluating Postprandial Glycemic Response to Three Sweetener Preloads Consumed Before a Standardized Mixed Meal in Healthy Adults
This study is using a double-blind, randomize crossover evaluating the impact of three different sweeteners on postprandial glycemic response in a mixed meal setting. In 50 individuals, postprandial glucose response will be evaluated as a primary objective. Secondary objectives include additional measures of glucose response as well general gastrointestinal response to the sweeteners, assessed through a series of questionnaires.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: John B Jarman, PhD
- Número de telefone: 323-325-1327
- E-mail: bryce@loamscience.com
Locais de estudo
-
-
California
-
San Francisco, California, Estados Unidos, 94109
- Recrutamento
- Alethios
-
Contato:
- Zeenia Framroze
- Número de telefone: 650-206-8006
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults 18 or older
- Body mass index between 18.5 and 29.9 kg/m2, inclusive, based on self-reported height and weight.
- Self-reported general good health, without a diagnosis of diabetes or prediabetes.
- Willing and able to consume the standardized study breakfast, consisting of a plain bagel with plain cream cheese, on six specified mornings.
- Willing to wear a continuous glucose monitor continuously on the upper arm for approximately 10 consecutive days.
- Willing to observe an overnight fast of at least 8 hours before each test morning and to follow test-day standardization instructions.
- Owns a compatible smartphone with reliable internet access and is willing to install the required study and sensor applications.
- Resides in the United States and is able to receive shipments at a residential address.
- Able to read, understand, and communicate in English.
- Willing and able to provide electronic informed consent through a digital platform.
Exclusion Criteria:
- Diagnosis of type 1 diabetes, type 2 diabetes, prediabetes, or a history of gestational diabetes.
- Current use of any glucose-lowering medication, including insulin, metformin, sulfonylureas, GLP-1 receptor agonists, DPP-4 inhibitors, or SGLT2 inhibitors.
- Current or recent use, within 30 days of consent, of systemic corticosteroids or any other medication known to materially alter glucose metabolism.
- Celiac disease, wheat or gluten allergy or intolerance, or any dairy allergy or lactose intolerance that would preclude consumption of the standardized study breakfast or exclusion of gluten or dairy from the diet for any other reason that would preclude consumption of the standardized breakfast.
- Known allergy or sensitivity to steviol glycosides, sucrose, or any declared component of the study preloads.
- Known adhesive allergy or history of significant skin reaction to wearable sensors or medical adhesives.
- Diagnosed gastrointestinal condition affecting digestion or absorption, including inflammatory bowel disease, gastroparesis, or prior bariatric or major gastrointestinal surgery.
- Current eating disorder, or a diagnosed eating disorder within the previous 12 months.
- Pregnant, breastfeeding, or planning to become pregnant during the study period.
- Regular night-shift work, or planned travel across more than two time zones during the study period.
- Planned substantial change in diet, physical activity, or body weight during the study period.
- Current alcohol use disorder or substance use disorder.
- Participation in another interventional research study within 30 days of consent or concurrently with this study.
- Any condition or circumstance that, in the judgment of the Principal Investigator, would compromise participant safety or the integrity of the study data.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Sequence 1
Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order. |
A fiber-based sweetener produced by LOAM. Table sugar Stevia |
|
Experimental: Sequence 2
Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order. |
A fiber-based sweetener produced by LOAM. Table sugar Stevia |
|
Experimental: Sequence 3
Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order. |
A fiber-based sweetener produced by LOAM. Table sugar Stevia |
|
Experimental: Sequence 4
Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order. |
A fiber-based sweetener produced by LOAM. Table sugar Stevia |
|
Experimental: Sequence 5
Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order. |
A fiber-based sweetener produced by LOAM. Table sugar Stevia |
|
Experimental: Sequence 6
Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order. |
A fiber-based sweetener produced by LOAM. Table sugar Stevia |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postprandial Area Under the Curve to 120 Minutes
Prazo: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Area under the curve above baseline from time zero (the start of the preload consumption) through 120 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded. |
Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postprandial Area Under the Curve to 180 Minutes
Prazo: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Area under the curve above baseline from time zero (the start of the preload consumption) through 180 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded. |
Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
|
Postprandial Area Under the Curve to 120 Minutes Relative to Start of the Meal
Prazo: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Area under the curve above baseline from time zero (the start of the meal consumption) through 120 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded. |
Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
|
Peak Glucose
Prazo: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Maximum observed glucose peak over the course of the 180 minute window. |
Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
|
Incremental Peak Glucose
Prazo: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Maximum observed glucose peak relative to baseline over the course of the 180 minute window. |
Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
|
Time to Peak
Prazo: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Elapsed time from preload consumption to the maximum observed value. |
Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
|
Post-Meal Subjective State
Prazo: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Fullness, hunger, energy, and gastrointestinal comfort on a 0-10 numerical rating scale with 10 being an optimal situation and 0 representing the inverse for fullness, energy, and gastrointestinal comfort and 0 being an optimal situation and 10 representing the inverse for hunger. Questions are asked 60 and 180 minutes after the start of the mixed meal. |
Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LOA003
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
IPD is proprietary information.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .